Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Summary

The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.

Timeline

Start

2022-02-17

Primary completion

2024-03-11

Completion

2024-04-02

Publications

• Franjic D, Fountaine RJ, Nalpas C, Goswami B, Fullerton T. Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. PLoS One. 2026 Mar 4;21(3):e0342907. doi: 10.1371/journal.pone.0342907. eCollection 2026.

Drugs

Indications